EventsAntibiotics 2026—Advances in Antimicrobial Action and Resistance
Published
This submission belongs to the session S2. Antimicrobials, Antimicrobial Resistance, and One Health of the event Antibiotics 2026—Advances in Antimicrobial Action and Resistance
Published date
04 May, 2026
Academic Editor
author-avatarJordi Vila
Citation
GEORGIOS-NIKOLAOS KARTANOS, Anastasia Anastasiadou, Maria Kyritsi, Antiopi Tsoureki, Zoi Thomou, Sofia Michailidou, Evangelos Kiossis, Anagnostis Argiriou, Fotis Psomopoulos, Victoria Siarkou, Unravelling blaIMP carbapenemase gene genetic context in dairy cattle and environmental metagenomes, in Proceedings of Antibiotics 2026—Advances in Antimicrobial Action and Resistance, Barcelona, 11 May–14 May 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Unravelling blaIMP carbapenemase gene genetic context in dairy cattle and environmental metagenomes

Zoi Thomou 3
Evangelos Kiossis 4
image
image
1. Laboratory of Microbiology and Infectious Diseases, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece., Greece
2. Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece., Greece
3. Pecon Hellas SMPC, Kastoria, Greece., Greece
4. Clinic of Farm Animals, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece., Greece
5. Laboratory of Molecular Genetics and Functional Genomics, Department of Food Science and Nutrition, School of the Environment, University of the Aegean, Myrina, Lemnos, Greece.
Abstract

INTRODUCTION: Carbapenemase-producing organisms (CPOs) pose a major global health threat. According to EARS-Net, Greece has one of Europe’s highest CPO-incidences in healthcare-associated infections, endemic for KPC, NDM, VIM, and OXA-48-like-carrying CPOs, but not for IMP. This study was conducted on metagenomes recovered from intensive dairy farms in Greece and harbored blaIMP-determinants to explore their genetic context and dynamics underlying blaIMP-dissemination, adopting a One Health-related approach.

METHODS: Short reads and contigs were comparatively analyzed using BLASTn, MEGA, and Easyfig software; assembled with MEGAHIT; and mapped to references (MZ816709.1, AJ550807.1) using Burrows-Wheeler-Aligner and SAMtools.

RESULTS: Analyses revealed that blaIMP-associated reads were identical or highly similar to blaIMP-13. Numerous reads and contigs covered the entire length of a Tn402-like transposon, including transposase (tnpA/R/M, tniA/B) and mercury-resistance (merRTPCADE) genes and a class-1 integron harboring blaIMP-13 variant, aac(6′), aadA1, qacEdelta1, and sul1, but lacking qacG2 genes.

DISCUSSION/CONCLUSIONS: Tn402-like transposons as carriers of class-1 integrons harboring blaIMP-13 variants have mainly been restricted to isolates from human clinical settings, promoted by the intensive use of carbapenems in these environments. Since carbapenems are banned from use in food-producing animals, it is surprising to note this highly mobile genetic element to be recovered from dairy cattle feces and environments. This suggests that any associated horizontal transfer could introduce blaIMP-13 variants into novel hosts, with the human–agricultural interface being a critical hotspot for spillovers. Given that blaIMP has not yet been reported in human clinical settings in Greece, moving personnel from areas with high blaIMP-13-carrying CPO incidence could be a potential source, creating secondary reservoirs and forming a cycle that changes traditional epidemiological boundaries. This is highly concerning, as widely used veterinary antibiotics could provide co-selection pressure, favoring the spread of blaIMP-13-variant-carrying CPOs. Our findings highlight the need for proactive metagenomic surveillance and strengthened monitoring strategies.

Keywords
antibiotic resistance
metagenomics
blaIMP carbapenemase gene
class-1 integron
transposon
dairy-cattle
environment
public health
EARS-Net (European Antimicrobial Resistance Surveillance Network)
Evaluation of Antibiotic Use in Patients Admitted to the Intensive Care Unit (ICU) with Pneumonia–Sepsis: Retrospective Observational Before–After Study

Advance in Developing Antimicrobial Peptides with Systemic Efficacy